Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLIC-1901
- Development stage
- Phase 2
- Lead developer
- Ottawa Hospital Research Institute
- Modality
- Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CLIC-1901 is an investigational, autologous chimeric antigen receptor (CAR) T cell therapy targeting CD19. It is developed for the treatment of relapsed or refractory CD19-positive hematologic malignancies, including acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). The therapy involves collecting a patient’s own T cells, genetically modifying them to express a CAR that recognizes the CD19 antigen on malignant B cells, expanding these modified cells ex vivo, and then infusing them back into the patient. Upon administration, these engineered CAR-T cells bind to and induce selective cytotoxicity against CD19-expressing tumor cells. The product is manufactured fresh (non-cryopreserved), aiming for rapid turnaround from collection to infusion[1][2][3][4].
- Other names
- autologous anti-CD19 CAR-expressing T lymphocytesautologous anti-CD19 Chimeric Antigen Receptor T cells
02
Targets
Beyond the preview
Go deeper on CLIC-1901.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLIC-1901.